Dr. Meyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000Fax+1 650-498-5840
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2010 - 2013
Stanford University School of MedicineClass of 2008
Certifications & Licensure
CA State Medical License 2009 - 2025- American Board of Internal Medicine Hematology
Clinical Trials
- Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
- Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD Start of enrollment: 2013 Jul 01
- Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant Start of enrollment: 2015 Aug 06
- Join now to see all
Publications & Presentations
PubMed
- Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.Michelle M Chin, John S Tamaresis, Laura J Johnston, Robert Lowsky, Everett Meyer
Bone Marrow Transplantation. 2024-11-18 - Hybrid allogeneic bone marrow transplant rescue approach after acute myelogenous leukaemia relapse in a high-risk patient.Alejandro Villar-Prados, Vanessa E Kennedy, Everett H Meyer
British Journal of Haematology. 2024-11-01 - Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.Surbhi Sidana, Andriyana K Bankova, Hitomi Hosoya, Shaji K Kumar, Tyson H Holmes
Blood Cancer Journal. 2024-10-09
Abstracts/Posters
- Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)Everett H Meyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel AgentsEverett H Meyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Authored Content
- Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023
Press Mentions
Immune Reconstitution with Orca-T Reveals ‘New Realm of Engineered Donor Grafts’ for Patients with Hematologic MalignanciesDecember 11th, 2022- Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021
- First Clinical Data from Ongoing Orca-T Trial Shows Significantly Improved 12-Month Graft Versus Host Disease (GvHD)-Free and Relapse-Free Survival (GRFS) in Blood Cancer Patients Receiving a Hematopoietic Stem Cell Transplant (HSCT)December 6th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
